Sucraid
Drug
QOL Medical, LLC
Total Payments
$3.5M
Transactions
43,997
Doctors
8,470
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $1.5M | 16,708 | 5,305 |
| 2022 | $93,380 | 2 | 0 |
| 2021 | $470,262 | 46 | 1 |
| 2020 | $827,395 | 3,787 | 1,495 |
| 2019 | $138,725 | 9,994 | 2,674 |
| 2018 | $205,212 | 6,563 | 1,896 |
| 2017 | $288,470 | 6,897 | 2,244 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.0M | 144 | 57.6% |
| Food and Beverage | $752,422 | 43,121 | 21.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $480,233 | 331 | 13.5% |
| Honoraria | $123,464 | 148 | 3.5% |
| Consulting Fee | $86,638 | 23 | 2.4% |
| Travel and Lodging | $27,679 | 216 | 0.8% |
| Grant | $25,000 | 1 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $4,000 | 2 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,500 | 1 | 0.1% |
| Education | $385.17 | 10 | 0.0% |
Payments by Type
Research
$2.0M
144 transactions
General
$1.5M
43,853 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of the Association of Genetic Sucrase-Isomaltase Deficiency (GSID) Allele Frequencies from Formalin Fixed Paraffin Embedded (FFPE) Tissue Samples with Low Sucrase Activity/DAR | QOL Medical, LLC | $792,749 | 0 |
| QOL Pediatric Sucraid | QOL Medical, LLC | $467,258 | 0 |
| Congenital Sucrase Isomaltase Deficiency (CSID) Screening Study in Adults > 18 years | QOL Medical, LLC | $346,924 | 0 |
| Sucrase-Isomaltase Deficiency in Irritable Bowel Syndrome and Diarrhea - Hiding in Plain Sight? | QOL Medical, LLC | $178,823 | 0 |
| QOL Fructan | QOL Medical, LLC | $81,025 | 0 |
| FFPE/DAR | QOL Medical, LLC | $79,552 | 0 |
| Prospective evaluation of the prevalence of sucrose malabsorption in patients referred for testing for small intestinal bacterial overgrowth | QOL Medical, LLC | $34,102 | 0 |
| An Adult Pilot Study to Establish the Reference Ranges and Optimal Cut-offs for the Oral 50g Sucrose Challenge Test and the 13C-Sucrose Breath Test for CSID Cases (Previously Diagnosed Sucraid Responders) and Controls (GI Asymptomatic Healthy Volunteers) | QOL Medical, LLC | $25,630 | 0 |
| A Multi Center Study of the Prevalence of Known Congenital Sucrase Isomaltase Deficiency (CSID) Genetic Variants and Functional Sucrase Activity by 13C Sucrose Breath Test in Children with Chronic Diarrhea or Chronic Abdominal Pain | QOL Medical, LLC | $14,176 | 0 |
| Functional sucrase deficiency in short bowel syndrome patients with intestinal failure | QOL Medical, LLC | $13,483 | 0 |
| A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid? (Sacrosidase) Oral Solution in Subjects with Chronic Diarrhea and Sucrase Deficiency | QOL Medical, LLC | $5,500 | 0 |
| SID | QOL Medical, LLC | $1,759 | 0 |
| C13 TESTING FOR SIBO PATIENTS | QOL Medical, LLC | $1,031 | 0 |
| A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid (Sacrosidase) Oral Solution in Subjects with Chronic Diarrhea and Sucrase Deficiency | QOL Medical, LLC | $500.00 | 0 |
Top Doctors Receiving Payments for Sucraid
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Minneapolis, MN | $2.2M | 193 |
| , D.O | Gastroenterology | Evanston, IL | $142,594 | 212 |
| , MD | Pediatric Gastroenterology | Atlanta, GA | $84,598 | 62 |
| , MD | Gastroenterology | Sioux Falls, SD | $35,519 | 92 |
| , D.O | Pediatrics | Oklahoma City, OK | $35,067 | 73 |
| , MD | Internal Medicine | New York, NY | $28,718 | 147 |
| , MD | Gastroenterology | Mobile, AL | $22,864 | 33 |
| , M.D | Internal Medicine | Columbus, OH | $20,656 | 33 |
| , MD | Gastroenterology | Columbus, OH | $19,378 | 35 |
| , M.D | Specialist | Charleston, SC | $13,458 | 24 |
| , FNP-C | Family | Avondale, AZ | $12,622 | 50 |
| , MD | Pediatrics | Los Angeles, CA | $11,463 | 18 |
| , MD | Pediatric Gastroenterology | Orlando, FL | $9,952 | 10 |
| , M.D | Pediatric Gastroenterology | Boca Raton, FL | $7,789 | 56 |
| , M.D | Gastroenterology | New York, NY | $6,947 | 125 |
| , M.D | Gastroenterology | Charlotte, NC | $6,615 | 27 |
| , MD | Pediatric Gastroenterology | Atlanta, GA | $6,343 | 7 |
| , M.D | Pediatric Gastroenterology | Akron, OH | $6,306 | 20 |
| , M.D | Gastroenterology | Covington, LA | $6,221 | 33 |
| , MD | Gastroenterology | Riverton, UT | $6,172 | 29 |
| , MD | Internal Medicine | Ann Arbor, MI | $5,805 | 5 |
| , MD | Gastroenterology | New York, NY | $5,481 | 83 |
| , M.D., M.P.H | Gastroenterology | Miami, FL | $5,339 | 61 |
| , M.D | Gastroenterology | Cherry Hill, NJ | $5,077 | 35 |
| , MD | Gastroenterology | Newport Beach, CA | $4,781 | 41 |
Ad
Manufacturing Companies
- QOL Medical, LLC $3.5M
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 8,470
- Transactions 43,997
About Sucraid
Sucraid is a drug associated with $3.5M in payments to 8,470 healthcare providers, recorded across 43,997 transactions in the CMS Open Payments database. The primary manufacturer is QOL Medical, LLC.
Payment data is available from 2017 to 2023. In 2023, $1.5M was paid across 16,708 transactions to 5,305 doctors.
The most common payment nature for Sucraid is "Unspecified" ($2.0M, 57.6% of total).
Sucraid is associated with 14 research studies, including "A Study of the Association of Genetic Sucrase-Isomaltase Deficiency (GSID) Allele Frequencies from Formalin Fixed Paraffin Embedded (FFPE) Tissue Samples with Low Sucrase Activity/DAR" ($792,749).